← All organizations
Highest phase reached
Phase 3
Timeline
1990s
- Jun 1, 1999
Innate Pharma— Founded
2010s
- Sep 13, 2018
moxetumomab pasudotox— Marketing Organization
- Sep 13, 2018
moxetumomab pasudotox— NDA Secondary Org
Drugs by trial phase (19 distinct, 25 trials)
Phase 3 (2 own, 0 via acquisition)
Phase 2 (11 own, 0 via acquisition)
Phase 1 (6 own, 0 via acquisition)
Indications
Studied for
- Adenocarcinoma
- Arthritis
- Arthritis, Rheumatoid
- Carcinoma
- Carcinoma, Squamous Cell
- Esophageal Neoplasms
- Esophageal Squamous Cell Carcinoma
- Head and Neck Neoplasms
- Inflammation
- Leukemia
- Leukemia, Lymphocytic, Chronic, B-Cell
- Leukemia, Lymphoid
- Leukemia, Myeloid
- Leukemia, Myeloid, Acute
- Lymphoma
- Lymphoma, T-Cell
- Lymphoma, T-Cell, Cutaneous
- Lymphoma, T-Cell, Peripheral
- Multiple Myeloma
- Mycoses
- Mycosis Fungoides
- Neoplasms
- Neoplasms, Plasma Cell
- Pneumonia
- Recurrence
- Sezary Syndrome
- Smoldering Multiple Myeloma
- Squamous Cell Carcinoma of Head and Neck
Marketed drugs (1)
Recent trials (28)
- NCT06781983Lead sponsorPhase 1Jan 24, 2025
- NCT06088654Lead sponsorPhase 1/Phase 2Oct 7, 2023
- NCT05742607Lead sponsorPhase 2Jun 23, 2023
- NCT05321147Lead sponsorPhase 1Mar 17, 2022
- NCT05143970CollaboratorPhase 1Nov 29, 2021
- NCT04984837CollaboratorPhase 2Aug 30, 2021
- NCT04742725Lead sponsorPhase 2May 25, 2021
- NCT04742725Overall official - principal investigatorPhase 2May 25, 2021
- NCT04742725Study chairPhase 2May 25, 2021
- NCT04590963CollaboratorPhase 3Oct 2, 2020
- NCT04371367CollaboratorPhase 2Apr 27, 2020
- NCT03902184Lead sponsorPhase 2May 13, 2019
- NCT03665129Lead sponsorPhase 1Sep 30, 2018
- NCT03307941CollaboratorPhase 1/Phase 2Jul 20, 2017
- NCT02921685CollaboratorPhase 1Oct 1, 2016
Details
- Founded
- Marseille, FR Jun 1, 1999
- Last known activity
- Jan 24, 2025